Collagenase Enzyme Injection for Stenosis and BPH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for tracheal and subglottic stenosis, as well as benign prostatic hyperplasia, are often invasive and have significant adverse consequences, with limited effectiveness, particularly in advanced cases, due to their reliance on collagen-based scar tissue and dense collagen networks.
Innovation Solution
The use of Collagenase Clostridium histolyticum (EN3835), a combination of Clostridial class I and II collagenases, is injected locally to break down collagen at the site of stenosis or prostate enlargement, targeting the collagen structural matrix and minimizing systemic exposure to dissolve scar tissue and reduce prostate size.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (surgery, dilation, stenting) are used for tracheal stenosis and BPH, then structural opening can be achieved, but invasive procedures and significant adverse consequences occur
Solution Approach 1:
The patent replaces mechanical interventions (surgical resection, balloon dilation, stenting) with a biochemical system using collagenase enzyme injection. The enzyme chemically degrades collagen scar tissue through hydrolysis, achieving airway or urethral patency without mechanical trauma, thus eliminating the adverse consequences associated with invasive procedures while maintaining treatment effectiveness
Solution Approach 2:
The patent changes the fundamental treatment parameter from mechanical force application to enzymatic chemical reaction. By injecting collagenase directly into the scar tissue, the treatment utilizes biochemical parameter changes (enzyme-catalyzed collagen degradation) rather than mechanical parameters (force, pressure, physical removal), thereby achieving therapeutic effect with minimal invasiveness
2Productivity
If invasive surgical procedures are performed to remove scar tissue or dilate airways, then immediate opening can be achieved, but risks of impotence, incontinence and re-treatment increase
Solution Approach 1:
The patent substitutes mechanical surgical procedures with enzymatic degradation. Collagenase injected into the scar tissue progressively breaks down collagen fibers through biochemical hydrolysis, achieving structural opening without the mechanical trauma that causes impotence, incontinence, or requires re-treatment. The biochemical process is inherently more selective and controllable than mechanical intervention
Solution Approach 2:
The injected collagenase enzyme performs self-service by autonomously degrading the collagen scar tissue through its catalytic activity. The enzyme penetrates the scar tissue and continuously breaks down collagen fibers without requiring external mechanical assistance, thereby achieving structural opening while avoiding the harmful effects associated with surgeon-performed mechanical procedures
3Volume of moving object
If collagen-based scar tissue is targeted for removal, then stenosis can be reduced, but invasive methods cause significant side effects
Solution Approach 1:
The patent extracts and selectively targets the collagen component of scar tissue for removal while preserving surrounding healthy structures. Collagenase enzyme specifically binds to and degrades collagen fibers through hydrolysis, extracting the pathogenic collagen matrix without affecting adjacent non-collagen tissues, thereby reducing stenotic volume with minimal side effects
Solution Approach 2:
The collagenase enzyme serves as a biochemical intermediary that mediates between the treatment goal (scar removal) and the target tissue (collagen matrix). The enzyme acts as a selective agent that translates the therapeutic intent into specific collagen degradation through its catalytic activity, achieving volume reduction of stenotic areas while sparing surrounding tissues from invasive damage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
EN3835 effectively reduces the size of stenotic areas and prostate tissue with minimal side effects, offering a safer and more effective alternative to traditional treatments by localized action and limited systemic toxicity.
Implementation Method 1
Collagenase Clostridium histolyticum (EN3835), a combination of Clostridial class I and II collagenases, is injected locally to break down collagen at the site of stenosis or prostate enlargement, targeting the collagen structural matrix
Data Source
AI summary
Collagenase Clostridium histolyticum (EN3835) is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions. EN3835 targets the collagenase structural matrix at the site of injection and does not require systemic exposure. Embodiments include methods of lysing subdermal collagen to treat various conditions such as benign prostatic hyperplasia, tracheal stenosis, subglottic stenosis and scleroderma.